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Summary
Objective:  The  present  study  describes  the  clinical,  radiological  and  histological  features  of
pharyngeal  synovial  sarcoma,  on  the  basis  of  one  clinical  case,  and  discusses  management.
Case study:  A  male  patient,  aged  27  years,  presented  with  synovial  sarcoma  of  the  lateral
pharyngeal  wall,  revealed  by  pharyngeal  discomfort  and  bloody  sputum.  CT  and  MRI  showed  a
partially necrotic  tumoral  process  centered  on  the  upper  half  of  the  piriform  sinus.  Pathologic
analysis  found  a  malignant  biphasic  tumor,  suggestive  of  synovial  sarcoma.  Partial  pharyngola-
ryngectomy  was  performed  on  a  lateral  approach,  with  associated  radiotherapy.
Discussion:  Synovial  sarcoma  raises  diagnostic  and  therapeutic  issues.  Prognostic  factors  are
not clearly  established.
Conclusion:  Pharyngeal  synovial  sarcoma  is  a  rare  tumor.  Treatment  is  essentially  surgical,
requiring  wide  margins;  radiotherapy  is  usually  associated.  The  value  of  chemotherapy  has
yet to  be  assessed.
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Introduction
Synovial  sarcoma  is  a  rare  malignant  tumor,  representing
some  10%  of  soft-tissue  sarcomas  [1].  It  generally  involves
the  extremities  of  the  limbs,  in  adolescents  and  young
adults,  with  a  predominantly  male  sex  ratio  [1].
Head  and  neck  locations  represent  only  0.7%  to  10%  of
synovial  sarcomas,  according  to  the  study  [1,2].
The  ﬁrst  ENT  location,  reported  by  Jernstrom  in  1954,
was  pharyngeal  [3].
We  present  a  case  of  synovial  sarcoma  of  the  lateral  pha-
ryngeal  wall,  with  an  update  on  management.∗ Corresponding author.
E-mail address: clementinedaveau@neuf.fr (C. Daveau).
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ase report
 27-year-old  man  consulted  for  recurrent  pharyngeal  dis-
omfort  with  recent  bloody  sputum.  He  had  no  relevant
istory  except  smoking  (15  pack-years).
Endoscopy  revealed  a  submucosal  lesion  with  an
lcerated  area  in  the  inferior  part  of  the  three  left  folds  and
xtending  along  the  lateral  pharyngeal  wall  up  to  the  infe-
ior  extremity  of  the  amygdala.  Palpation  found  bilateral
atellite  adenopathies  (areas  IIa  and  III).
Cervico-thoracic  CT  with  contrast  injection  found  a
5  ×  24  ×  33  mm  tissue  lesion  centered  on  the  superior  half
f  the  left  piriform  sinus,  with  hypervascular  blushes  extend-
ng  laterally  to  the  primitive  carotid  (segmental  deletion  of
at  between  tumor  and  carotid  artery)  (Fig.  1A  and  B);  the
resence  of  adenopathies  was  conﬁrmed.  Chest  examination
as  normal.
Contrast-enhanced  MRI  found  a  35  ×  23  ×  28  mm  lesion
n  T2  hypersignal  and  T1  isosignal,  with  strong  uptake,
served.
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wigure  1  Contrast-enhanced  cervical  CT:  tissue  injury,  hetero
he upper  half  of  the  left  piriform  sinus.  A:  coronal  slice.  B:  fro
specially  in  the  periphery,  and  heterogeneous  center,
xerting  a  mass  effect  on  the  airway  without  arterial  hyper-
ascularity  or  bone,  cartilage  or  vascular  invasion  (Fig.  2A
nd  B).
Anatomopathologic  biopsy  analysis  diagnosed  malignant
iphasic  synovial  sarcoma  of  intermediate  grade  on  the
NCLCC  classiﬁcation,  with  characteristic  SYT-SSX1  tran-
cript.  The  tumor  cells  were  PS100-negative.
PET-scan  showed  signiﬁcant  metabolic  activity  (SUV
.5  to  8)  in  the  lesion,  with  several  bilateral  cervical
s
s
a
igure  2  SPAIR  T2  MRI  with  gadolinium  injection:  tissue  damage  
ith a  heterogeneous  center  on  the  left  lateral  pharyngeal  wall.  A:  ous,  partially  necrotic  hypervascular  with  blushes,  centered  on
slice.
denopathies  (SUV  4.5  to  5)  without  secondary  loca-
ion.
As  the  tumor  was  operable  with  low  chemosensitivity,  the
DT  meeting  decided  on  partial  pharyngolaryngectomy  on  a
ateral  approach  with  bilateral  curage  associated  to  inferior
ediculated  sternocleidomastoid  ﬂap  and  tracheotomy.
Anatomopathology  conﬁrmed  a  2-cm  diameter  bipha-ic  synovial  sarcoma  (Fig.  3A  and  B)  associated  with
evere  purulent  inﬂammatory  reaction  of  the  stroma
nd  peritumoral  tissue,  with  positive  resection  margins
in  strong  T2  hypersignal,  strongly  enhanced  in  the  periphery,
coronal  slice.  B:  frontal  slice.
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tFigure  3  Coexistence  of  the  two  cell  types:  spindle  and  gland
of synovial  sarcoma.  A:  low  magniﬁcation.  B:  magniﬁcation  ×  40
(R1).  There  were  no  lymph  node  metastases,  but  severe
lymphoid  follicular  hyperplasia,  sinus  histiocytosis,  and
sinus  congestion  with  ganglions  up  to  2.5  cm  in  diameter
(pT1N0M0).
The  patient  underwent  revision  for  premature  detach-
ment  of  scar  tissue  at  D15,  managed  by  transoral
coagulation.  Postoperative  course  was  otherwise  free  of
complications;  feeding  was  resumed  at  D10  and  the  naso-
gastric  tube  was  removed  at  D18,  with  discharge  at  D23.
Complementary  tumor-site  radiation  therapy  was  ini-
tiated  at  D45  (60  Gy,  2  Gy/fractions,  6  weeks).  The
tracheotomy  cannula  was  left  in  place  until  1  month  after
RT  termination.
No  chemotherapy  was  applied.
No  recurrence  was  noted  at  22  months’  FU.
Discussion
The  present  case  was  typical  of  literature  reports:  pharyn-
golaryngeal  location  [4],  young  patient  [1,4—8], male  [4—8],
low  lymphophilia  [4].  The  biphasic  aspect  was  characteristic
although  not  the  most  frequently  observed  [4,5].
Overall,  5-year  survivorship  in  head  and  neck  synovial
sarcoma  is  around  40%  to  60%  [4—8].
Histologically,  synovial  sarcoma  comprises  variable  pro-
portions  of  epithelial  and  spindle  cells.  The  difﬁculty  of
histological  diagnosis  leads  to  misdiagnosis,  especially  of
monophasic  tumors,  for  which  the  differential  diagnoses
are  ﬁbrosarcoma,  malignant  schwannoma  and  hemangiope-
ricytoma.  Histochemical  and  immunohistochemical  analysis
are  then  mandatory,  frequently  ﬁnding  t(X;18)  (p11.2;q11.2)
translocation  [4,6,7].
Some  synovial  sarcomas  can  be  poorly  differentiated  and
aggressive,  with  high  metastatic  potential.
The  tissue  origin  of  synovial  sarcoma  remains  unknown,
but  is  not  in  the  synovial  tissue.  Risk  factors  are  not  well
established.
There  is  no  correlation  between  histologic  tumor  type
and  clinical  expression  [1].
The  consensus  is  in  favor  of  primary  surgery,  with
broad  resection  that  may  sacriﬁce  bone  and/or  nerve.
Several  reports  [5,6]  recommended  systematic  postope-
rative  radiation  therapy,  although  Giaoui  et  al.  [4]  pre-
fer  simple  surveillance  for  T1  pharyngolaryngeal  lesions
D
T
cepithelial  cells,  indicative  of  the  characteristic  biphasic  nature
n young  patients,  unless  resection  margins  are  insufﬁ-
ient.  Cadman  et  al.  [1]  reported  no  improvement  in
ortality  with  postoperative  radiation  therapy,  although
ocal  recurrence  was  reduced  in  all  synovial  sarcoma  loca-
ions.
It  is  noteworthy  that  there  were  peroperative  difﬁculties
n  distinguishing  tissue  inﬂammation  from  the  tumor  as  such;
maging  signiﬁcantly  overestimated  tumor  size.  The  litera-
ure  does  not  mention  this  issue.  There  is  thus  a  role  for
xtemporaneous  examination  [4].
There  has  been  no  demonstration  of  beneﬁt  from
ssociating  chemotherapy  to  postoperative  radiation  ther-
py  in  synovial  sarcoma,  as  series  have  been  too  small;
hemotherapy  is  therefore  not  indicated  [5].  However,  a
eta-analysis  of  all  resectable  sarcomas,  including  10%
ynovial  sarcomas,  found  that  doxorubicin  chemotherapy
igniﬁcantly  delayed  local  recurrence  and  remote  metasta-
is  and  increased  overall  recurrence-free  survival  although
ot  overall  survival  as  such  [9].
Metastasis  is  mainly  to  the  lungs,  followed  by  lymph
odes  and  bone  [1],  and  may  sometimes  be  of  late  onset
2,6].
Prognostic  factors  are  difﬁcult  to  demonstrate,  due  to
he  small  size  of  series.  In  orthopedic  forms,  less  than  5  cm
umor  diameter  seemed  to  be  of  good  prognosis  [10]. Other
tudies  reported  male  gender,  age  less  than  20  years,  suf-
cient  resection  margins  that  neighboring  vital  structures
akes  it  difﬁcult;  and  absence  of  delay  in  diagnosis  as  fac-
ors  of  good  prognosis  [4—7].
onclusion
ead  and  neck  synovial  sarcoma  is  a  rare  tumor  and  con-
titutes  a  challenge  for  both  diagnosis  and  treatment,
equiring  multidisciplinary  management.  The  possible  ben-
ﬁt  of  doxorubicin  potentialization  should  be  examined  in
he  hope  of  improving  prognosis.isclosure of interest
he  authors  declare  that  they  have  no  conﬂicts  of  interest
oncerning  this  article.
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